1-(carboxymethylthio)tetradecane and Dyslipidemias

1-(carboxymethylthio)tetradecane has been researched along with Dyslipidemias in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Berge, RK; Bohov, P; Gudbrandsen, OA; Husebye, ES; Løvås, K; Rustan, AC; Røst, TH; Skorve, J; Ulvik, RJ; Wensaas, AJ	1

Trials

1 trial(s) available for 1-(carboxymethylthio)tetradecane and Dyslipidemias

Article	Year
Tetradecylthioacetic acid attenuates dyslipidaemia in male patients with type 2 diabetes mellitus, possibly by dual PPAR-alpha/delta activation and increased mitochondrial fatty acid oxidation. Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:4 Topics: Adult; Blood Glucose; Blood Pressure; Body Weight; Cells, Cultured; Diabetes Mellitus, Type 2; Dyslipidemias; Fatty Acids; Humans; Hypolipidemic Agents; Lipid Metabolism; Lipids; Lipoproteins; Male; Middle Aged; Muscle Fibers, Skeletal; PPAR alpha; PPAR delta; Sulfides; Tumor Cells, Cultured	2009

Article

Year

Tetradecylthioacetic acid attenuates dyslipidaemia in male patients with type 2 diabetes mellitus, possibly by dual PPAR-alpha/delta activation and increased mitochondrial fatty acid oxidation.

Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:4

Topics: Adult; Blood Glucose; Blood Pressure; Body Weight; Cells, Cultured; Diabetes Mellitus, Type 2; Dyslipidemias; Fatty Acids; Humans; Hypolipidemic Agents; Lipid Metabolism; Lipids; Lipoproteins; Male; Middle Aged; Muscle Fibers, Skeletal; PPAR alpha; PPAR delta; Sulfides; Tumor Cells, Cultured

2009